PT - JOURNAL ARTICLE AU - Foley, Deirdre F AU - Chege, Timothy K AU - Kabagenyi, Joyce AU - McCarthy, Karen AU - Gicheru, Elijah T AU - Kibinge, Nelson AU - Maina, Angela W AU - Waeni, Jacqueline M AU - Clemens, Ralf AU - Clemens, Sue-Ann Costa AU - Tuju, James AU - Sande, Charles J TI - The landscape of paediatric infectious disease exposure in a rural sub-Saharan Africa setting in Kilifi, Kenya: longitudinal serological analysis over two decades and priorities for future vaccine development AID - 10.1101/2024.01.10.24300883 DP - 2024 Jan 01 TA - medRxiv PG - 2024.01.10.24300883 4099 - http://medrxiv.org/content/early/2024/01/10/2024.01.10.24300883.short 4100 - http://medrxiv.org/content/early/2024/01/10/2024.01.10.24300883.full AB - Background The paucity of data on the contemporary causes of serious infection among the world’s most vulnerable children means the landscape of emerging paediatric infectious disease remains largely undefined and out of focus on the global vaccine research and development agenda.Methods We aimed to partially define the paediatric infectious disease landscape in a typical low-income setting in sub-Saharan Africa in Kilifi, Kenya by simultaneously estimating antibody prevalence for 38 infectious diseases using a longitudinal birth cohort that was sampled between 2002 and 2008 and a paediatric inpatient cohort that was sampled between 2006 and 2017.Findings Among the infectious diseases with the highest antibody prevalence in the first year of life were vaccine-preventable diseases such as RSV (57.4%), mumps (31.5%) and influenza H3N2 (37.3%). Antibody prevalence for Plasmodium falciparum shifted substantially over time, from 47% in the mid 2000s to 13% approximately 10 years later corresponding to a documented decline in parasite transmission. A high prevalence of antibodies was also observed in the first year of life for infections for which no licenced vaccines are currently available, including norovirus (34.2%), cytomegalovirus (44.7%), EBV (29.3%) and coxsackie B virus (40.7%). The prevalence to antibodies to vaccine antigens in the local immunisation schedule was generally high but varied by antigen.Interpretation The data show a high and temporally stable infection burden of RSV, mumps and influenza, providing a compelling evidence base to support progress towards the introduction of these vaccines into the local immunization schedule. The high prevalence of norovirus, EBV, CMV and Coxsackie B provide rationale for increased vaccine research and development investment.Funding This research was funded by the Wellcome Trust (grant no. WT105882MA).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Wellcome TrustAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Scientific Ethics Research Unit of the Kenya Medical Research Institute gave ethical approval for this work. The parents and legal representatives of all the children in this study provided written informed consent prior to recruitment into the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors